XEN901 (Nav1.6 inhibitor)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 05/17/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Phase 1
Sponsors and Collaborators
Xenon Pharma
Mechanism of Action
Ion Channel
Mechanism Description
Sodium Channel inhibitor
Populations Tested In
drug resistant focal epilepsy, rare epilesies with sodium channel mutations
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
N/A
Clinical Trial link